Retatrutide vs Tirzepatide vs Semaglutide: Who Wins?
In clinical trials, retatrutide produced the most weight loss of the three, followed by tirzepatide, then semaglutide. But more weight loss comes with less long-term data and, for retatrutide, no FDA approval yet.
Quick Answer
Semaglutide (one receptor, ~15% weight loss), tirzepatide (two receptors, ~20 to 22%), and retatrutide (three receptors, ~24%) all work by activating metabolic gut hormone receptors . Each step up in receptor targets produces more weight loss in trials, but also comes with less long-term safety data. Semaglutide and tirzepatide are FDA approved; retatrutide is not yet available.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist injected once per week. GLP-1 is a hormone that tells your brain you are full and slows digestion.
It is sold as Ozempic (for blood sugar control) and Wegovy (for weight loss). It has been on the market since 2017 and has more long-term data than the others.
What Is Tirzepatide?
Tirzepatide activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide, a second gut hormone). Hitting both receptors at once appears to drive more weight loss than GLP-1 alone .
It is sold as Mounjaro (diabetes) and Zepbound (weight loss). It is injected once per week.
What Is Retatrutide?
Retatrutide is a "triple agonist" that hits GLP-1, GIP, and a third receptor called the glucagon receptor. Adding glucagon may increase how many calories you burn at rest .
As of 2026, retatrutide is still in clinical trials and is not FDA approved. Phase 2 data showed up to 24% weight loss over 48 weeks at the highest dose .
How Do These Three Drugs Differ?
How does each one work?
Semaglutide activates the GLP-1 receptor only. This reduces appetite and slows gastric emptying.
Tirzepatide adds GIP activation on top of GLP-1. GIP may further enhance insulin release and could affect fat tissue directly .
Retatrutide adds the glucagon receptor to both. Glucagon receptor activation may raise your resting metabolic rate, meaning you burn more calories even when not moving .
How much weight loss do trials show?
Semaglutide (Wegovy): about 15% average body weight loss at 2.4 mg weekly over 68 weeks .
Tirzepatide (Zepbound): about 20 to 22% at 15 mg weekly over 72 weeks .
Retatrutide: up to 24% at the highest dose over 48 weeks in Phase 2 . Note: Phase 2 trials are smaller than Phase 3 trials and may not reflect final real-world results.
What is the FDA approval status?
Semaglutide: FDA approved for diabetes (Ozempic) and weight loss (Wegovy).
Tirzepatide: FDA approved for diabetes (Mounjaro) and weight loss (Zepbound).
Retatrutide: not approved as of 2026. Still in late-stage trials.
How long has each been studied in humans?
Semaglutide has the longest track record, with cardiovascular outcome data now published .
Tirzepatide has several years of real-world use and growing outcomes data.
Retatrutide is the newest. Long-term data beyond 48 weeks is not yet available.
What are the common side effects?
All three share the same GLP-1 class side effects: nausea, vomiting, diarrhea, and constipation. These usually peak during dose increases.
Retatrutide's glucagon component may add mild increases in heart rate, as seen in some participants in trials .
How Do All Three Compare Side by Side?
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptors targeted | GLP-1 | GLP-1, GIP | GLP-1, GIP, glucagon |
| Average weight loss | ~15% [verify] | ~20 to 22% [verify] | ~24% [verify] |
| Injection frequency | Weekly | Weekly | Weekly |
| FDA approval | Yes | Yes | No (as of 2026) |
| Long-term safety data | Most available | Growing | Very limited |
| Availability | Widely available | Widely available | Not commercially available |
| Brand names | Ozempic, Wegovy | Mounjaro, Zepbound | None yet |
Which Do People Pick, and When?
People starting out or working with a physician who wants proven data usually start with semaglutide. It has the most history and the most insurance coverage.
People who tried semaglutide and want more results often move to tirzepatide. The weight loss numbers are meaningfully higher.
People researching retatrutide are typically either in a clinical trial or following research closely, since it is not yet commercially available.
This is general guidance about how people approach these decisions. It is not personalized medical advice. These are prescription drugs. A physician who knows your health history should guide your choice.
If you are managing a titration schedule across weekly injections, tracking how you feel at each dose level is useful data. DoseVault makes it easy to log your current dose, record side effects by week, and build a clear picture of how a drug is working for you.
Frequently Asked Questions
What is the difference between semaglutide, tirzepatide, and retatrutide?
Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 and GIP). Retatrutide activates three (GLP-1, GIP, and glucagon). Each additional receptor target adds roughly 5 percentage points of average body weight loss in trials, but also increases novelty and reduces long-term safety data.
How much weight do you lose on each drug?
Semaglutide 2.4 mg weekly averages about 15% body weight loss in 68-week trials . Tirzepatide 15 mg weekly averages about 20 to 22% in trials . Retatrutide showed up to 24% in early Phase 2 trials . All numbers are averages and individual results vary.
Is retatrutide approved by the FDA?
No. As of 2026, retatrutide is not FDA approved. It is still in clinical trials. Tirzepatide is FDA approved (as Mounjaro for diabetes and Zepbound for weight loss). Semaglutide is FDA approved (as Ozempic for diabetes and Wegovy for weight loss).
Which drug should I ask my doctor about?
This is general guidance, not personalized medical advice. For someone seeking the most evidence and the widest availability, semaglutide or tirzepatide are the current options. Retatrutide is not yet commercially available. Your doctor can review your full history and help you decide.
Related
- Retatrutide
- Tirzepatide
- Do You Lose Weight Back After Stopping GLP-1?
- Semaglutide vs Retatrutide
- Semaglutide vs Tirzepatide
- Peptides for Fat Loss
- How to Reconstitute Retatrutide
Disclaimer
This article is for educational purposes only and is not medical advice. Semaglutide and tirzepatide are prescription drugs. Retatrutide is not FDA approved. Do not use any medication to diagnose, treat, cure, or prevent any condition without guidance from a licensed clinician. Clinical trial averages do not predict individual results.
Built by medical professionals, gym rats, and experienced biohackers
Tracking a weekly injection schedule or logging your dose increases? DoseVault keeps your full protocol history in one place so you and your doctor can review what is actually working.